المؤلفون: Der-Ren Hwang, Yu-Shan Wu, Chun-Wei Chang, Tzu-Wen Lien, Wei-Cheng Chen, Uan-Kang Tan, John T.A. Hsu and Hsing-Pang Hsieh

المساهمون: 徐祖安

مصطلحات موضوعية: Sesquiterpene lactones, Parthenolide, Hepatitis C virus replicon, Anti-HCV agents

الوقت: 24

وصف الملف: application/pdf; 295008 bytes

العلاقة: Bioorganic & Medicinal Chemistry, Elsevier, Volume 14, Issue 1, 1 January 2006, Pages 83-91; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38349Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38349Test

المؤلفون: Der-Ren Hwang, Hsin-Yu Lai, Ming-Ling Chang, John T.A. Hsu, Chau-Ting Yeh

المساهمون: 徐祖安

مصطلحات موضوعية: Emergence, mutation, clusters, HCV, genome, during, sequential, viral, passages, Sip-L, expressing, cells

الوقت: 24

وصف الملف: application/pdf; 261828 bytes

العلاقة: Journal of Virological Methods, Elsevier, Volume 129, Issue 2, November 2005, Pages 170-177; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38317Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38317Test

المؤلفون: Guang-Zhou Leu, Tiao-Yin Lin, John T.A. Hsu

المساهمون: 徐祖安

مصطلحات موضوعية: HCV, Replicon, Polyunsaturated fatty acids including arachidonic acid, Eicosapentaenoic acid, Docosahexaenoic acid

الوقت: 24

وصف الملف: application/pdf; 253966 bytes

العلاقة: Biochemical and Biophysical Research Communications, Elsevier, Volume 318, Issue 1, 21 May 2004, Pages 275-280; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38276Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/38276Test

المؤلفون: 盧俊龍

المساهمون: 林志侯

مصطلحات موضوعية: C型肝炎病毒複製酶, 虛擬藥物篩選, 電腦輔助藥物篩選, 分子對接藥物篩選, HCV NS5B, HCV RNA-dependent RNA polymerase, Non-structure protein NS5B, virtual docking, CADD, PScore, DOCK

الوقت: 37

وصف الملف: 155 bytes; text/html

العلاقة: 1.(a)Memon,M.I.;Memon,M.A.J.Viral.Hepat.2002,9,84(b)Moradpour,D.;Cerny,A.;Heim,M.H.;Blum,H.E. Swiss Med Weekly 2001,131,291 2.For a review of HCV epidemiology, pathogenesis, and clinical treatment, see：(a)Lauer, G. M.;Walker, B. D. N. Engl. J.Med. 2001,345,41;(b)Di Bisceglie, A. M. Lancet 1998, 351,351 3.For a clinical overview of HCV, see:Strader, D. B.;Seeff, L. B. ILAR J. 2001,42,107 4.Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNAdependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 277, 11149–11155 (2002) 5. Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov. 2002 Nov;1(11):867-81 6. Friebe, P., Lohmann, V., Krieger, N. & Bartenschlager, R. Sequences in the 5′?nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 2001 75, 12047–12057 7. Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep. C Viruses 2000 242, 55–84 7.Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep. C Viruses 2000 242, 55–84 8. Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 2002 277, 11149–11155 9. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 1998 282, 938–941 Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999 57,223–229 10. Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999 57,223–229 11. Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 1999 96, 12766–12771 12. Bartenschlager, R. & Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000 81, 1631–1648 13. Bukh, J., Miller, R. H. & Purcell, R. H. Genetic heterogeneity of hepatitis C virus — quasispecies and genotypes. Semin.Liv. Dis. 1995 15, 41–63 14.www.prn.org/./models/ img_pgs/hcv.3d.med.htm 15.www.genelabs.com/ research/antiviral.html 16. http://www.hopkins-gi.org/pages/latin/templates/index.cfmTest 17.Kolykhalov, A. A., Mihalik, K., Feinstone, S. M. & Rice, C. M.Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74, 2046–2051 (2000) 18.Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570–574 (1997). 19. Leveque, V. J.-P. & Wang, Q. M. RNA-dependent RNA polymerase encoded by hepatitis C virus: biomedical applications. Cell. Mol. Life Sci. 59, 909–919 (2002). 20. http://dock.compbio.ucsf.edu/DOCK_5/index.htmTest 21. http://sw16.im.med.umich.edu/software/xtool/manual/trouble.htmlTest 22. http://www.rcsb.org/pdbTest/ 23. 3-(4-AMINO-2-TERT-BUTYL-5-METHYL-PHENYLSULFANYL)- 6-CYCLOPENTYL-4-HYDROXY-6-[2-(4-HYDROXY-PHENYL)- ETHYL]-5,6-DIHYDRO-PYRAN-2-ONE 24. Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California 92121 Received 14 January 2003/Accepted 2 April 2003 25. Ago, H., T. Adachi, A. Yoshida, M. Yamamoto, N. Habuka, K. Yatsunami, and M. Miyano. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417–1426. 26. Bressanelli, S., L. Tomei, A. Roussel, I. Incitti, R. L. Vitale, M. Mathieu, R. De Francesco, and F. A. Rey. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 96:13034–13039. 27. Lesburg, C. A., M. B. Cable, E. Ferrari, Z. Hong, A. F. Mannarino, and P. C. Weber. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937–943. 28. Labonte, P., V. Axelrod, A. Agarwal, A. Aulabaugh, A. Amin, and P. Mak. 2002. Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis. J. Biol. Chem. 277:38838–38846. 29. Qin, W., H. Luo, T. Nomura, N. Hayashi, T. Yamashita, and S. Murakami. 2002. Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J. Biol. Chem. 277:2132–2137. 30. Wang, Q. M., M. A. Hockman, K. Staschke, R. B. Johnson, K. A. Case, J. Lu, S. Parsons, F. Zhang, R. Rathnachalam, K. Kirkegaard, and J. M. Colacino. 2002. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76:3865–3872. 31. Yamashita, T., S. Kaneko, Y. Shirota, W. Qin, T. Nomura, K. Kobayashi, and S. Murakami. 1998. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the Cterminal region. J. Biol. Chem. 273:15479–15486. 32. Bressanelli, S., L. Tomei, F. A. Rey, and R. De Francesco. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482–3492. 33. (2Z)-2-(BENZOYLAMINO)-3-[4-(2-BROMOPHENOXY)PHENYL]- 2-PROPENOIC ACID 34. Jeffrey A. Pfefferkorn, Meredith L. Greene, Richard A. Nugent, Rebecca J. Gross, Mark A. Mitchell, Barry C. Finzel, Melissa S. Harris, Peter A. Wells, John A. Shelly, Robert A. Anstadt, Robert E. Kilkuskie, Laurice A. Kopta and Francis J. Schwende . Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. Bioorganic & Medicinal Chemistry Letters 15 (2005) 2481–2486. 35. (a) Jacob-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D.; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320; (b) Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Science 1998, 282, 1669. 36. Jeffrey A. Pfefferkorn, Richard Nugent, Rebecca J. Gross, Meredith Greene, Mark A. Mitchell, Matthew T. Reding, Lee A. Funk, Rebecca Anderson, Peter A. Wells, John A. Shelly, Robert Anstadt, Barry C. Finzel, Melissa S. Harris, Robert E. Kilkuskie, Laurice A. Kopta and Francis J. Schwendea.Inhibitors of HCV NS5B polymerase. Part 2:Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid. Bioorganic & Medicinal Chemistry Letters 15 (2005) 2812–2818.; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/30924Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/30924Test

المؤلفون: 盧建勝, Chien-Sheng Lu

المساهمون: 林志侯教授

مصطلحات موضوعية: C型肝炎病毒, 藥效基團, CATALYST軟體, HCV, PHARMACOPHORE, CATALYST PROGRAM

الوقت: 37

وصف الملف: 155 bytes; text/html

العلاقة: 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 1989 244, 359–362 2. Hoofnagle, J. H. Hepatitis C — the clinical spectrum of disease. Hepatology 1997 26, S15–S20 . 3. Willems, M., Metselaar, H. J., Tilanus, H. W., Schalm, S. W. & de Man, R. A. Liver transplantation and hepatitis C. Transplant Int. 2002 15, 61–72 4. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S121-7 5. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol.; 2000 242:55-84 6. Friebe, P., Lohmann, V., Krieger, N. & Bartenschlager, R. Sequences in the 5′?nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 2001 75, 12047–12057 7. Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep. C Viruses 2000 242, 55–84 8. Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov. 2002 Nov;1(11):867-81 9. Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 2002 277, 11149–11155 10. Bartenschlager, R. & Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000 81, 1631–1648 11. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 1998 282, 938–941 12. Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 1999 57,223–229 13. Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 1999 96, 12766–12771 14. Bukh, J., Miller, R. H. & Purcell, R. H. Genetic heterogeneity of hepatitis C virus — quasispecies and genotypes. Semin.Liv. Dis. 1995 15, 41–63 15. Zein, N. N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000 13, 223–235 16. Farci, P. & Purcell, R. H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liv. Dis. 2000 20, 103–126 17. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol. 2000 Feb;74(4):2046-51 18. De Francesco, R. et al. Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Sem. Liv. Dis. 2000 20, 69–83 19. Yao, N. H., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999 7, 1353–1363 20. Dymock, B. W., Jones, P. S. & Wilson, F. X. Novel approaches to the treatment of hepatitis C virus infection. Antivir. Chem. Chemother. 2000 11, 79–96 . 21. Ingallinella, P. et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry 2002 41, 5483–5492 22. Zhang, R. M., Durkin, J. P. & Windsor, W. T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg. Med. Chem. Lett. 2002 12, 1005–1008 23. Bennett JM, Campbell AD, Campbell AJ, Carr MG, Dunsdon RM, Greening JR, Hurst DN, Jennings NS, Jones PS, Jordan S, Kay PB, O'Brien MA, King-Underwood J, Raynham TM, Wilkinson CS, Wilkinson TC, Wilson FX. The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase. Bioorg Med Chem Lett. 2001 Feb 12;11(3):355-7 24. Priestley ES, De Lucca I, Ghavimi B, Erickson-Viitanen S, Decicco CP. P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2002 Nov 4; 12(21) : 3199-202 25. Slater MJ, Andrews DM, Baker G, Bethell SS, Carey S, Chaignot H, Clarke B, Coomber B, Ellis M, Good A, Gray N, Hardy G, Jones P, Mills G, Robinson E. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3359-62 26. Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139, USA 27. Boehringer Ingelheim (Canada) Ltd, Laval, Que´bec, H7S 2G5, Canada 28. Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997 277, 570–574 29. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001 May; 15(5):411-28 30. Schrödinger LLC.Portland, 2003. 31. The Cambridge Crystallographic Data Centre 12 Union Road, Cambridge, CB2 1EZ, UK, 32. Sybyl Tripos Associates: St. Louis, MO, 33. Catalyst, version 4.9 (software package); Accelrys, Inc. (previously known as Molecular Simulations, Inc.): San Diego, 2004. 34. Debnath, A. K Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors. J. Med. Chem.; 2004 47(3); 768-768 35. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem., 1983 4, 187-217 36. Smellie, A. Poling: Promoting Conformational Variation. J. Comput. Chem., 1995 16, 171-187. 37. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage. 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995 35, 285-294 38. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Space. 2. Application of Conformational Models J. Chem. Inf. Comput. Sci. 1995 16, 295-304 39. Catalyst tutorials release 4.7; Accelrys, Inc. San Diego, 2002 40. http://www.hopkins-gi.org/pages/latin/templates/index.cfmTest 41. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151-185. 42. Saladino, R.; Crestini, C.; Palamara, A. T.; Danti, M. C.; Manetti, F.; Corelli, F.; Garaci, E.; Botta, M. Synthesis, Biological Evaluation, and Pharmacophore Generation of Uracil, 4(3H)-Pyrimidone, and Uridine Derivates as Potent and Selective Inhibitors of Parainfluenza 1 (Sendai) Virus. J. Med. Chem. 2001, 44, 4554-4562. 43. Tafi, A.; Costi, R.; Botta, M.; Di Santo, R.; Corelli, F.; Massa, S.; Ciacci, A.; Manetti, F.; Artico, M. Antifungal Agents. 10. New Derivates of 1-[(Arly)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole,Synthesis, Anti-Candida Activity, and Quantitative Structure-Analysis Relationship Studies. J. Med. Chem. 2002, 45, 2720-2732. 44. Singh, J.; van Vlijmen, H.; Liao, Y.; Lee, W.; Cornebise, M.; Harris, M.; Shu, I.; Gill, A.; Cuervo, J. H.; Abraham, W. M.; Adams, S. P. Identification of Potent and Novel R4‚1 Antagonists Using in Silico Screening. J. Med. Chem. 2002, 45, 2988-2993. 45. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411. 46. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E.G.; Lan, L.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Mol. Pharmacol. 2002,61, 974-981. 47. Dziadulewicz, E. K.; Ritchie, T. J.; Hallett, A.; Snell, C. R.; Davies, J. W.; Wrigglesworth, R.; Dunstan, A. R.; Bloomfield, G. C.; Drake, G. S.; McIntyre, P.; Brown, M. C.; Burgess, G. M.;Lee, W.; Davis, L.; Yaqoob, M.; Phagoo, S. B.; Phillips, E.; Perkins, M. N.; Campbell, E. A.; Davis, A. J.; Rang, H. P. Nonpeptide Bradykinin B2 Receptor Antagonists: Conversion of Rodent-Selective Bradyzide Analogues into Potent, Orally Active Human Bradykinin B2 Receptor Antagonists. J. Med. Chem. 2001, 45, 2160-2172. 48. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fourier, A.; Klabunde, T. Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Resonance Studies on Urotensin II. J. Med. Chem. 2002, 45, 1799-1805. 49. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsutsumi, K.; Nasu, M.; Moriyasu, M. Discovery of Novel Mesangial Cell Proliferation Inhibitors Using a Three-Dimensional Database Searching Method. J. Med. Chem. 2001, 44, 2304-2307. 50. Chen, G. S.; Chang, C.; Kan, W. M.; Chang, C.; Wang, K. C.; Chern, J. Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal inhibitors of Rat 5R-Reductase. J. Med. Chem. 2001, 44, 3759-6763. 51. Palomer, A.; Pascual, J.; Cabre´, F.; Luisa, M.; Mauleo´n, D. Derivation of Pharmacophore and CoMFA Models for Leukotriene D4 Receptor Antagonists of the Quinolinyl(bridged)aryl Series. J. Med. Chem. 2000, 43, 392-400. 52. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112. 53. Barbaro, R.; Betti, L.; Botta, M.; Corelli, F.; Giannacchini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Corsano, S. Synthesis, Biological Evaluation, and Pharmacophore Generation of New Pyridazinone Derivates with Affinity toward R1- and R2- Adrenoceptores. J. Med. Chem. 2001, 44, 2118-2132. 54. Ekins, S.; Durst, G. L.; Stratford, R. E.; Thorner, D. A.; Lewis, R.; Lonarich, R. J.; Wikel, J. H. Three-Dimensional Quantitative Structure-Permeability Relationship Analysis for a Series of Inhibitors of Rhinovirus Replication. J. Chem. Inf. Comput. Sci. 2001, 41, 1578-1586. 55. Bureau, R.; Daveu, C.; Lemaýˆtre, S.; Dauphin, F.; Landelle, H.; Lancelot, J.; Rault, S. Molecular Design Based on 3D-Pharmacophore. Application to 5-HT4 Receptor. J. Chem. Inf. Comput. Sci. 2002, 42, 962-967. 56. Glunz PW, Douty BD, Decicco CP. Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorg Med Chem Lett. 2003 Mar 10;13(5):785-8. 57. Zhang X, Schmitt AC, Jiang W, Wasserman Z, Decicco CP. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1157-60. 58. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004 Apr 23;279(17):17508-14. Epub 2004 Feb 06. 59. Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinas-Brunet M, Nar H, Lamarre D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection Angew Chem Int Ed Engl. 2003 Mar 28;42(12):1356-60.; http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/28613Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/28613Test

المؤلفون: 盧建勝, Chien-Sheng Lu

المساهمون: 林志侯教授

مصطلحات موضوعية: C型肝炎病毒, 藥效基團, CATALYST軟體, HCV, PHARMACOPHORE, CATALYST PROGRAM

الوقت: 37

وصف الملف: 1152426 bytes; application/octet-stream

العلاقة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/7052Test

الإتاحة: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/7052Test